{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "25807752", "DateCompleted": {"Year": "2015", "Month": "04", "Day": "21"}, "DateRevised": {"Year": "2021", "Month": "10", "Day": "06"}, "Article": {"Language": ["rus"], "ArticleDate": [], "ELocationID": [], "Journal": {"ISSN": "1728-2985", "JournalIssue": {"Issue": "5", "PubDate": {"Year": "2014", "Season": "Sep-Oct"}}, "Title": "Urologiia (Moscow, Russia : 1999)", "ISOAbbreviation": "Urologiia"}, "ArticleTitle": "[Clinical-biochemical and immunological parameters in the diagnosis and treatment of chronic pyelonephritis on the background of intercurrent diseases].", "Pagination": {"StartPage": "14", "EndPage": "18", "MedlinePgn": "14-8"}, "Abstract": {"AbstractText": ["Studies have shown that complicated chronic pyelonephritis in the active phase is characterized by structural and functional instability cytomembranes and decreased immunological resistance of the patient man. Supplement standard antibiotic treatment with ozone therapy antioxidant immunomodulation drug thus received immunobiochemical study."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [], "LastName": "Ermishina", "ForeName": "V I", "Initials": "VI"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Kazeko", "ForeName": "N I", "Initials": "NI"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Berdichevski\u012d", "ForeName": "V B", "Initials": "VB"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Mendelian", "ForeName": "Sh S", "Initials": "ShS"}, {"Identifier": [], "AffiliationInfo": [], "LastName": "Il'iasov", "ForeName": "S Zh", "Initials": "SZh"}], "PublicationTypeList": ["Clinical Trial", "Journal Article"]}, "MedlineJournalInfo": {"Country": "Russia (Federation)", "MedlineTA": "Urologiia", "NlmUniqueID": "100900900", "ISSNLinking": "1728-2985"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Bacterial Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "5EXP385Q4F", "NameOfSubstance": "Luminol"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "KFG2PZR7UX", "NameOfSubstance": "sodium luminolate"}], "MeshHeadingList": [{"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Anti-Bacterial Agents"}, {"QualifierName": ["administration & dosage", "therapeutic use"], "DescriptorName": "Antioxidants"}, {"QualifierName": [], "DescriptorName": "Chronic Disease"}, {"QualifierName": [], "DescriptorName": "Combined Modality Therapy"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": ["drug effects", "enzymology", "metabolism"], "DescriptorName": "Erythrocyte Membrane"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug effects"], "DescriptorName": "Immune System Phenomena"}, {"QualifierName": ["drug effects"], "DescriptorName": "Lipid Peroxidation"}, {"QualifierName": ["administration & dosage", "analogs & derivatives", "therapeutic use"], "DescriptorName": "Luminol"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Ozone"}, {"QualifierName": ["blood", "complications", "immunology", "therapy"], "DescriptorName": "Pyelonephritis"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2015", "Month": "3", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "3", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "4", "Day": "22", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["25807752"]}}], "PubmedBookArticle": []}